IMMUNOSILENCING Fc VARIANTS
AssigneeVisterra, Inc.
InventorsKarthik Viswanathan, Lauren Olinski, Ramki Ramakrishnan, Aditi Deshpande, Gregory Babcock, Zachary Shriver
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things Fc variants that have significantly reduced ADCC, ADCP and CDC function As described herein, the present disclosure is, in part based on identification of novel combinations of mutations that abolish binding to all FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, FcγRIIb, and C1q.
Claims9
1-39. (canceled)
An antibody comprising an Fc variant of a wild-type human IgG4 Fc region, said Fc variant comprising amino acid substitutions of S228P, F234V, L235E, and D265G, wherein the residues are numbered according to the EU index.
An antibody comprising an Fc variant of a wild-type human IgG1 Fc region, said Fc variant comprising amino acid substitutions of L234F, L235E, D265G, A330S, and P331S, wherein the residues are numbered according to the EU index.
Dependencies are inferred from the claim text.